Company Overview
VYNE Therapeutics Inc. operates as a clinical-stage biopharmaceutical company dedicated to developing therapies aimed at treating chronic inflammatory and immune-mediated conditions. The firm functions within the broader Healthcare sector, specifically specializing in the Biotechnology industry, which implies a focus on high-risk, high-reward research and development activities prior to potential commercialization. This specialized entity maintains a relatively small operational scale, employing 10 individuals and maintaining a total market capitalization of $19.70M. The company's annual revenue over the trailing twelve months stands at $570,000, figures that collectively indicate a nascent stage of development where the entity is likely still allocating significant resources toward clinical trials rather than established commercial sales. The modest market cap combined with minimal revenue suggests the company is in an early growth phase, relying heavily on external capitalization to fund its lead programs rather than generating substantial cash flow from operations.
Financial Health
VYNE Therapeutics reported a trailing twelve-month revenue of $570,000 while simultaneously recording a net income loss of $-26,736,000 and an EBITDA of $-29,726,000. The substantial disparity between the minimal revenue and the significant net loss reveals a cost structure driven almost entirely by research and development expenses and operational overhead rather than sales costs. The company generated a free cash flow of $-26,668,124, indicating a continued burn rate that necessitates ongoing fundraising to maintain operations and advance its therapeutic pipeline. Margin analysis shows a gross margin of 100.0%, reflecting low direct costs relative to sales, yet an operating margin of -4014.6% and a profit margin of 0.0% highlight severe operational inefficiencies typical of pre-revenue biotech firms. In terms of balance sheet strength, the company holds $29.01M in cash with no reported debt, although specific debt figures are not available, meaning the debt-to-equity ratio is listed as N/A. Despite the lack of explicit debt data, the presence of $29.01M in cash against negligible liabilities suggests a conservative liquidity position rather than a leveraged one. Short-term liquidity is further evidenced by a current ratio of 12.53, a figure that indicates the company possesses more than twelve times the current assets necessary to cover its current liabilities. Return metrics demonstrate negative returns on equity of -67.0% and return on assets of -38.3%, revealing that management has not yet generated positive returns on the capital invested in the business.
Valuation Assessment
Valuation metrics for VYNE present a complex picture due to the company's lack of profitable earnings, with a trailing P/E ratio of N/A and a forward P/E of -0.36. The negative forward P/E implies that the market is pricing in future earnings that are not yet realized, creating a theoretical premium or discount based on projected recovery rather than historical performance. The price-to-book ratio stands at 0.71, suggesting the market is currently valuing the company at a discount relative to its net asset value. Alternative valuation methods provide further context, with a price-to-sales ratio of 34.56 and an EV/EBITDA of 0.31, indicating that the stock is priced heavily against its sales volume while its enterprise value relative to earnings is low due to the massive negative earnings. Price action over the last year has ranged between a 52-week high of $1.99 and a 52-week low of $0.28, placing the current trading environment within a wide volatility band. The company exhibits a beta of 2.03, which means its stock price is expected to be twice as volatile as the broader market, reflecting the high risk associated with clinical-stage biotechnology investments.
Growth & Income
The company demonstrates robust top-line expansion with a revenue growth rate of 54.8% year-over-year, while earnings growth is listed as N/A due to the company's consistent losses. Since earnings are negative, they cannot grow faster or slower than revenue in a traditional sense, but the widening gap between revenue and net loss indicates that costs are rising faster than sales, a common pattern in scaling biotech operations. As a non-dividend payer, VYNE Therapeutics maintains a dividend yield of N/A and a payout ratio of 0.0%, confirming that the company retains all earnings to reinvest into its research programs rather than distributing income to shareholders. This reinvestment strategy is typical for clinical-stage firms that prioritize pipeline advancement over income distribution. Overall, the growth and income profile is characterized by significant revenue acceleration coupled with substantial cash consumption and a complete absence of dividend income, reflecting a capital-intensive growth strategy typical of early-stage biopharmaceutical development.